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Retinalganglioncell(RGC)lossafteropticnervedamageisahallmarkofcertainhumanophthalmicdiseasesincludingischemic
optic neuropathy (ION) and glaucoma. In a rat model of optic nerve transection, in which 80% of RGCs are eliminated within 14
days,caspase-2wasfoundtobeexpressedandcleaved(activated)predominantlyinRGC.Inhibition ofcaspase-2expressionby
a chemically modiﬁed synthetic short interfering ribonucleic acid (siRNA) delivered by intravitreal administration signiﬁcantly
enhanced RGC survival over a period of at least 30 days. This exogenously delivered siRNA could be found in RGC and other
types of retinal cells, persisted inside the retina for at least 1 month and mediated sequence-speciﬁc RNA interference without
inducing an interferon response. Our results indicate that RGC apoptosis induced by optic nerve injury involves activation of
caspase-2, and that syntheticsiRNAsdesigned toinhibit expressionof caspase-2represent potential neuroprotective agents for
intervention in human diseases involving RGC loss.
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Ocular neuroprotection, speciﬁcally the preservation of retinal
ganglion cells (RGC), is of particular interest as numerous
ocular pathologies, such as glaucoma and ischemic optic
neuropathy (ION), cause permanent loss of RGC, leading to
vision loss and blindness (for reviews see Schmidt et al.
1 and
Kisiswa et al.
2). RGCs are particularly susceptible possibly
because retrograde axonal transport of target-derived neuro-
trophic factors to RGC somata via the optic nerve (ON) is
compromisedowingtodamagetotheONinthesepathologies.
3
The ON transection model in adult rats initiates rapid onset and
progression of RGC death and is considered suitable for
studying mechanisms of RGC death and for testing the activity
of neuroprotective compounds.
4–7 In this model, apoptosis is
thought to account for the death of the majority of RGC.
Accordingly, treatments that inhibit apoptosis reduced the
number of dying RGC in this model. These include microglial
inhibitors,
8,9 glial or brain-derived neurotrophic factors
(BDNFs),
10 implantation of activated macrophages,
11 over-
expression of Bcl-2
12,13 and caspase inhibitors such as the
synthetic peptides Ac-Tyr-Val-Ala-Asp-aldehyde or benzyloxy-
carbonyl-Asp-Glu-Val-Asp-chloromethylketone.
14–16
The caspases are a family of cysteine proteases that
activate apoptotic pathways either as ‘initiators’ or ‘effectors’
(or ‘executioners’) based on their structural and functional
characteristics. The initiator caspases cleave and activate
executioner caspases (e.g. caspase-3 or -7), which, in turn,
hydrolyse important proteins eventually inducing apoptosis.
Caspase-2 is one of the most highly conserved caspases and
is unique in that it can act as both an initiator and an effector
caspase, depending on the apoptotic scenario.
17–25 Structu-
rally, caspase-2isaninitiator caspasebecauseofits longpro-
domain containing a caspase recruitment domain. Similar to
other initiator caspases, activation of caspase-2 occurs via
proximity-induced dimerization following recruitment to large
protein complexes. After dimerization (aggregation), auto-
cleavage of caspase-2 may take place, rendering it more
active than the full-length dimerized enzyme. Although
caspase-3-mediated cleavage of pro-caspase-2 has been
described, it is not a caspase-2 activation event.
26–29 In
response to a variety of treatments, activation of caspase-2
occurs predominantly in the cytosol via recruitment to a
protein complex termed PIDDosome acting downstream
to mitochondria activation in apoptosis pathways.
17–25 However,
caspase-2 activation can also occur independent of
PIDDosome and through death receptor pathways, such as
those triggered by TRAIL or FAS.
30–35 Unlike other initiator
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www.nature.com/cddiscaspases, caspase-2 does not directly activate the execu-
tioner caspases but, instead, signals death through activation
of mitochondrial apoptosis; hence, functioning as its potential
ampliﬁer.
36,37 The multifaceted participation of caspase-2 in
apoptosis following a variety of stresses, including DNA
damage, heat shock, stimulation of death receptors, cytoske-
letal disruption, endoplasmic reticulum stress and oxidative
stress,
38 makes it an attractive target for therapeutic
intervention in diseases associated with pathological cell
loss. For example, caspase-2-deﬁcient neurons are resistant
to apoptosis induced by b-amyloid
39,40 and activation of
caspase-2 is involved in apoptosis of hippocampal neurons
following transient global ischemia in rats.
41 Caspase-2 is
expressed in RGC of ischemic retinas,
42 and the neuropro-
tectiveeffectofBDNFinthismodelisassociatedwithreduced
levels of caspase-2 immunohistochemical staining.
43
However, there is no previous literature indicating that caspase-2
is speciﬁcally involved in RGC death after ON injury.
These studies were aimed at evaluating the contribution of
caspase-2 to RGC death in two adult rats ON injury models by
characterizing its expression pattern post-injury, inhibiting its
expression using caspase-2-speciﬁc short interfering ribonu-
cleic acid (siRNA) and testing the potential of this siRNA as a
novel neuroprotective agent. Here we show that after ON
injury caspase-2 is cleaved in RGC, most likely as a result of
pro-caspase-2 activation, and this cleavage represents an
importantfeatureoftheresultantRGCdeath.Wefurthershow
that inhibition of caspase-2 with an intravitreally administered
synthetic chemically modiﬁed siRNA protects RGC from
death after ON injury. The speciﬁc siRNA used in these rat
studies is now being evaluated in clinical studies and is being
developed for the treatment of ON injuries, including non-
arteritic anteriorischemic optic neuropathy (NAION), an acute
disease associated with RGC loss.
Results
Caspase-2 is expressed and cleaved in RGC after ON
crush. We examined caspase-2 mRNA expression in
retinas from either normal animals or animals subjected to
ON crush (ONC), which leads to retrograde death of the
entire RGC population by 21–30 days after the injury.
44–49
Caspase-2 mRNA was found to be enriched in RGC
compared with other types of cells in normal rat retinas as
detected by quantitative RT-PCR (qPCR) analysis of Thy1.1-
positive and -negative populations of retinal cells (Figure 1a
and Supplementary Figure 1). To examine caspase-2
localization in RGC after ON damage, we performed
comparative immunohistochemistry analysis in the ONC
model. In retinas from normal animals, low levels of total
caspase-2 protein were detected in a minority of RGC, and
no caspase-2-speciﬁc signal was detected with the
antibodies recognizing the cleaved version (upper panels of
Figures 1d and f, respectively). In contrast, the cleaved form
of caspase-2 was detectable in RGC one day after ONC,
demonstrating that processing of caspase-2 is rapidly
initiated in the retina after ON injury (Figures 1b and c).
Detection of cleaved caspase-2 at this time point, albeit at
abundance, correlated with the presence of few apoptotic
(TUNEL-positive) cells in the ganglion cell layer (GCL) (not
shown). By day 7 after ONC, increased total (Figures 1d and
e) and cleaved caspase-2 (Figures 1f and g) staining was
observed in greater than 90% of RGC, suggesting that
caspase-2 activation by both aggregation and subsequent
cleavage has a role in RGC apoptosis in this model.
Caspase-2 protein expression could also be detected in
occasional cells of the inner nuclear layer (INL).
To distinguish whether enhanced total caspase-2 staining
in RGC stemmed from the aggregation only or was also
accompanied by increase in the protein levels, we performed
western blot analysis and subsequent densitometry using
protein extracts from retinas harvested at day 7 after ONC.
The levels of both the pro- and cleaved forms of caspase-2
were elevated at 7 days after ONC compared with control
intact retinas (Supplementary Figure 2). In particular, the
12kDa cleaved fragment, which the antibody is directed
against, was elevated by twofold over controls after ONC
(Supplementary Figure 2b). These data demonstrated that
both levels of pro-caspase-2 protein and accumulation of its
cleaved form increased in rat retinas after ON injury.
As caspase-2 can be cleaved by caspase-3 without its
subsequentactivation,
26–29weperformedimmunohistochem-
ical analysis on post-ONC retinal sections, adjacent to those
shown in Figures 1d and f, and demonstrated that cleaved
caspase-3 was neither localized to bIII-tubulin-positive RGC
(Supplementary Figure 3a) nor to GFAP-positive astrocytes
(Supplementary Figure 3b) in the GCL, but rather was
localized to cells in the INL (arrowheads), suggesting that
caspase-3 was not responsible for RGC apoptosis nor the
presence of cleaved caspase-2 in RGC and the latter was
rather an indication of caspase-2 activation in these cells.
Moreover, the time kinetics of the abundance of caspase-2
activation in RGC is in a good agreement with previously
published data on the time kinetics of RGC apoptosis in the
ONC model.
4–7
Properties of siRNA targeting caspase-2. To verify the
functional involvement of caspase-2 in RGC apoptosis in the
ONC model, and to explore the possible protective effects of
caspase-2-targeted siRNAs in ON damage models of RGC
death, we designed a chemically modiﬁed synthetic siRNA
targeting caspase-2 (siCASP2) that is capable of inhibiting
both the human and rat caspase-2 orthologues. siCASP2
was tested initially in cell culture by qPCR for its ability to
elicit caspase-2 mRNA knockdown following transfection. In
human HeLa cells, siCASP2 exhibited an IC50 against
human caspase-2 mRNA of B0.8nM, and human
caspase-2 mRNA levels could be reduced by over 80%
(Figure 2a). Transfection of siCASP2 into rat PC12 cells
reduced rat caspase-2 mRNA levels by 65% (Supplementary
Figure 4a). This difference in potency of siCASP2 between
human HeLa and rat PC12 cells may be explained by better
accessibility of the siRNA target region in the human
compared with the rat transcript due to local secondary
structure (Supplementary Figure 5),
50 or may stem from
other reasons such as potential differences in transfection
efﬁciency or intrinsic RNA interference (RNAi) potency
between HeLa and PC12 cells. The chemical modiﬁcations
incorporated into siCASP2 conferred resistance to nucleases
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Cell Death and Diseasein serum (Supplementary Figure 4b) and vitreous humour
(Figure 2b) for at least 24h at 371C abrogating any potential
seed- and passenger-strand-mediated off-target effects
(Supplementary Figure 6), and blocked the ability of the
siRNA to activate innate immune responses as conﬁrmed by
lack of in vivo interferon responses (Figure 2c) and in vitro
cytokine production (Supplementary Figure 7).
siCASP2 is efﬁciently taken up by retinal cells
in vivo. To determine the efﬁciency of uptake of siCASP2
in the retina following intravitreal administration, we injected
a ﬂuorescent Cy3-labelled siRNA that contained chemical
modiﬁcations similar to siCASP2 and monitored its
distribution in the retina by ﬂuorescence-activated cell
sorting (FACS) analysis at 1 and 18h after injection
(Figure 3a). As evident, the whole Thy-1
þ retinal cell
population was positive for Cy3 staining, consistent with
siRNA uptake (Figure 3a). Similar results were obtained by
ﬂuorescence microscopy. In retinal whole mounts, Cy3-
labelled siRNA was found in up to 90% of retinal cells 5h
after intravitreal injection (Supplementary Figure 8a), and the
ﬂuorescent signal in these cells persisted for at least 24h
Figure 1 Caspase-2 is cleaved in RGC after ONC. (a) qPCR analysis of caspase-2 mRNA abundance in Thy1.1
þ (bound to magnetic beads coupled to anti-Thy1.1
antibodies) and other retinal cells (unbound). (b) Representative microphotographs of sections of rat retina 24h after ONC. Arrowheads show cleaved (p12) caspase-2
(C-CASP2) immunoreactivity (original magniﬁcation  40). (c) High-power images (original magniﬁcation x 63) of top panel in (b) demonstrating cleaved caspase-2
(C-CASP2) immunoreactivity (brown) in the GCL (arrowheads). (d) Double immunohistochemical staining shows that CASP2 (green; arrowheads) is present in higher
amounts at 7 days after ONC in RGC compared with intact control bIII-tubulin-positive RGC (red). The blocking peptide used as a negative control gave no CASP2
þ
immunoreactivity. (e) Percentage of CASP2/bIII-tubulin-double-positive cells among bIII-tubulin-positive cells, all in the ganglion cell layer±S.D. (i.e. RGC; calculationswere
made from 18 retinas per treatment and sampled from ﬁve different areas of each retina). (f) Double immunohistochemistry did not detect C-CASP2 (green) in RGC (red) of
intactcontrols, but did localizeC-CASP2(colocalization¼orange) in RGCat 7 dayspost-ONC scale bar (d) and (f)¼25mm; IHC¼immunohistochemistry, GCL¼ganglion
cell layer, INL¼inner nuclear layer, ONL¼outer nuclear layer, IPL¼inner plexiform layer, block pep¼blocking peptide). (g) Percentage of bIII-tubulin-positive cells in the
ganglion cell layer (RGC) also containing C-CASP2±S.D.
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Cell Death and DiseaseFigure 2 Target knockdown activity, nuclease stability and interferon response-inducing properties of siCASP2. (a) siCASP2 dose-dependent knockdown of caspase-2
mRNAinHeLacells±S.D.(b)AnalysisofsiCASP2integrityonnativepolyacrylamidegelfollowingincubationinsilicoinrabbitvitrealﬂuid.‘0’timepointcorrespondstosiRNA
aliquot dissolved in PBS (size control). (c) Induction of interferon (IFN)-responsive gene expression in rat retina/choroid after intravitreal injection of either 20mg of siCASP2,
5–20mgofpoly-(I:C)orPBS(n¼3–10),andtheexpressionofIFN-responsivegenes,IFIT1andOAS1B6(notshownasnoinductionofgeneexpressionwasdetectedatthis
time point in any group) analysed 24h later by quantitative RT-PCR. The results are expressed as % increase over control intact eyes (100%) (±S.D.) (IFIT1, interferon-
induced protein with tetratricopeptide repeats 1; OAS1B 6, 2’-5’-oligoadenylate synthase 1B 6)
Figure 3 Localization, stability and RNAi activity of intravitreally injected siCASP2. (a) Detection of Cy3 ﬂuorescence in isolated RGC 1h (red line) or 18h (green line)
followingsingleintravitrealinjectionof40mgCy3-siRNAperrateye.FACSanalysisdisplayingresultsobtainedfromrepresentativeoneoutoftworetinaltissuepoolsanalysed
per time point are shown. (b) Representative micro-autoradiographs of parafﬁn sections (counterstained with haematoxylin and eosin) from untreated ((i), (ii)) and siCASP2-
injected rat eyes ((iii)–(iv)), which were hybridized with either siCASP2-speciﬁc ((i)–(iv)) or with a nonspeciﬁc ((v), (vi)) control
33P-labelled probe ((i), (iii), (v)) – bright ﬁeld
images, ((ii), (iv), (vi)) – corresponding dark ﬁeld images. In dark ﬁeld images, hybridization signals are white dots over all retinal layers in sections of siCASP2-injected eyes
hybridized to the speciﬁc probe ((iv)) and were especially prominent in the GCL (arrow). No signal in the GCL is detected in control sections ((ii), (vi)) (exposure 24h, original
magniﬁcation  20). The eyes for in situ hybridization analysis were enucleated at 2h after intravitreal injection of 20mg siRNA. At least 10 eyes from each group were
analysedfrom2to3differentexperiments.(c)QuantiﬁcationofsiCASP2±S.D.inretinaatdifferenttimesafterintravitrealinjectionof20mgpereyesiCASP2(n¼6).Control
retinas were obtained from intact non-injected eyes. (d) Detection of siCASP2-mediated RNAi using RLM-RACE: (i) EtBr-stained agarose gel with electrophoresed RLM-
RACE products from siCASP2-transfected PC12 cells (size control) and from retinas collected at 4h after intravitreal injection of PBS (1); 20mg siCNL (2); or 20mg siCASP2
(3)(yellowboxesindicategel regionsexcisedforcloningand subsequent colonysequencing);(ii) autoradiographof theSouthernblot of thegelshown in(i) afterhybridization
with radiolabelled RLM-RACE junction-speciﬁc probe; and (iii) example of the results of colony sequencing showing the RLM-RACE junction corresponding to the expected
siCASP2 produced cleavage site. RLM-RACE was performed on RNA extracted from a pool of two retinas from eyes injected with PBS, pool of ﬁve retinas from the eyes
injected with siCNL or a pool of four retinas from the eyes injected with siCASP2
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Cell Death and Disease(Supplementary Figure 8b). Similar distribution data to that
obtained with Cy3-labelled siRNA were generated by in situ
hybridization detection of siCASP2 in the retina using a
radiolabelled siCASP2-speciﬁc oligonucleotide probe
complementary to its guide strand. The highest intensity
signal was observed in the GCL layer with lower intensity
signal in other layers of the retina (Figure 3b). Intact siCASP2
was quantiﬁable in the retina by the ‘Stem & Loop’ qPCR
method for as long as 28 days after a single intravitreal
injection (Figure 3c). Thus, the intravitreal delivery route for
targeting RGC is effective for siCASP2 as siCASP2 was
found to be taken up rapidly by RGC and to persist in the
retina for weeks. These data illustrate the remarkable
stability of this chemically modiﬁed synthetic siRNA in eye
tissues.
siCASP2 reduces caspase-2 mRNA in treated eyes. To
demonstrate that siCASP2 reduces target mRNA expression
in treated eyes is technically very demanding as RGC only
constitute o1% of the total retinal cell population and
caspase-2 mRNA expression level even in the enriched
RGC population is extremely low (10-fold less than that of
Thy1.1 mRNA and 100-fold less than NEFL mRNA –
Figure 1a and Supplementary Figure 1b). Nonetheless, we
dissected out retinae from siCASP2- and control-treated
eyes at either 72 or 96h post-injection, immunopanned
RGC using anti-Thy1.1 antibody-coupled beads (see
Supplementary Material and Methods section for details)
and performed qPCR analysis. We were able to demonstrate
a B50% reduction in caspase-2 mRNA level with siCASP2
treatment compared with control. However, these differences
did not reach statistical signiﬁcance (Supplementary Figures
9a and b).
siCASP2 induces speciﬁc RNAi-mediated caspase-2
mRNA cleavage in vivo. To verify that RNAi activity was
induced by siCASP2 in rat retinas after intravitreal
administration, we used the RNA ligase-mediated rapid
ampliﬁcation of cDNA ends (RLM-RACE) method to detect
the presence of caspase-2 mRNA-speciﬁc cleavage product
in rat retina. As evident from Figure 3d(ii), a band of the
expected size was detected only in retina samples from rat
eyes injected with siCASP2, and not from eyes injected with
vehicle (PBS) or negative control short interfering RNA
targeting control gene (siCNL). Cloning and sequencing of
the RACE products generated using retinal mRNA from
siCASP2-injected eyes and eluted from the gel (Figure 3c(i))
conﬁrmed that cleavage occurred at the expected site in the
caspase-2 mRNA (Figure 3d(iii)). In contrast, none of the 66
sequenced clones from vehicle-treated eyes and the 65
sequenced clones from control siCNL-treated eyes, obtained
by the same procedure, contained the predicted siCASP2-
mediated cleavage site.
siCASP2 protects RGC from apoptosis in two models of
acute ON injury. The neuroprotective effect of siCASP2
was assessed by counting the number of FluoroGold (FG)
back-labelled RGC in retinal whole mounts at 7 days
51,52
after ONC or at 14 days after ON transection (axotomy)
(ONT). In the ONC model, RGC axons were transected by
clamping, leaving the neural sheath and central retinal artery
intact. In the ONT model, all RGC axons and neural sheath
are completely severed without compromising the central
retinal artery. ONT induces a more acute and rapid loss of
RGC than ONC and is, therefore, a more aggressive model
for evaluating RGC neuroprotection.
53
In eyes treated with the negative control siCNL, 60% RGC
loss was apparent at 7 days post-ONC, whereas 490% of
RGC were still intact in eyes injected with 5mg of BDNF used
as a positive control (Figures 4a and b). Single intravitreal
administration of siCASP2 resulted in a dose-dependent
increaseinRGCsurvivalbetweensiRNAdosesof5and20mg
per eye. Doses of 20 and 35mg per eye resulted in RGC
densitiesthatwerecomparabletothatinintactretinas(B98%
of RGC preserved). Doses above 35mg per eye resulted in
reduced RGC protection relative to the optimal doses of 20
and 35mg per eye (Figures 4a and b). In spite of the reduced
efﬁcacy of high siCASP2 doses, a signiﬁcant neuroprotective
effect (Po0.01, analysis of variance (ANOVA)) was apparent
in all dose groups relative to the negative control. These
results suggest that a single intravitreal administration of
siCASP2 in the rat signiﬁcantly protects RGC from apoptosis
induced by ONC for at least 7 days. It is unclear as to why
efﬁcacywasreducedatdosesabove35mgasnooverttoxicity
was observed upon gross examination of the retinal whole
mounts.
In eyes similarly treated with 20mg of siCASP2 at days 0
and 10 after ONC, sustained neuroprotection was observed
even on day 30: siCASP2 maintained the mean viability of 12-
fold more RGC per mm
2 than in PBS-treated controls
(Supplementary Figure 10). This equated to a mean survival
of 48% of the total population of RGC found in control intact
retinas compared with o1% survival in PBS-treated controls.
In the ONT model, 10mg of siCASP2 or control siRNA
targeting green ﬂuorescent protein (siGFP) was administered
twice by intravitreal injection – once immediately after ONT
and again on day 7 post-ONT. Similar to the results obtained
in the ONC model, neuroprotection was also observed with
siCASP2 14 days after ONT in this more aggressive RGC
injury model, where RGC densities were greater by up to 2.5-
fold in eyes treated with siCASP2 relative to eyes treated with
the negative control siRNA, siGFP (Po0.01, ANOVA)
(Figures 4c and d).
Discussion
Death of RGC is the main cause of blindness in several
diseases, including glaucoma and NAION. ON injury models,
such as those used in our studies, are a valuable tool for
exploring mechanisms of RGC death and for screening
potential neuroprotective agents.
54–56 These models are
technically convenient as RGC axons are easily accessible
in the ON as a single population and therapeutic agents may
be applied to the RGC somata through intraocular injections.
The particular advantage of these models is that they allow
quantitative assessment of the capacity of pharmacological
agents to inﬂuence survival of RGCs after ON injury.
57,58
Moreover, pharmacological agents showing neuroprotective
efﬁcacy in these very aggressive models can be expected to
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typical for relevant human diseases.
The data reported here demonstrate that caspase-2 is
activated and autocleaved speciﬁcally in RGC after ON injury.
Boththepro-andthecleavedformsoftheenzymewerefound
to be elevatedin retinas of ONC eyes together with caspase-2
mRNA, indicating that the protein levels were also increased
after injury.
A single intravitreal injection of a synthetic chemically
modiﬁed siRNA targeting caspase-2 afforded almost com-
plete protection of RGC during the ﬁrst week after ONC,
maintaining enhanced survival for 30 days after ONC, and
signiﬁcantly improved RGC survival in the more severe and
prolonged ONT model. The magnitude of the neuroprotective
effectofsiCASP2intheONCmodelwascomparabletothatof
BDNF. To date, BDNF administration has been the most
effective neuroprotective strategy for preserving RGC for up
to 7 days in the aggressive axotomy model.
59,60 However,
sustained RGC protection has not been observed with BDNF
treatment
61 owing to the rapid downregulation of its high-
afﬁnity receptor, TrkB, in response to the ON injury.
62,63
Interestingly, published data suggest that the neuroprotective
effects of BDNF after retinal ischemia may be partially
mediated by BDNF-induced reduction of caspase-2 protein
levels.
64
Synthetic siRNAs capable of inducing sequence-speciﬁc
gene silencing are emerging as a potentially powerful new
class of therapeutics. Synthetic siRNAs are comprised of
short (15–27bp) double-stranded RNA capable of guiding
cleavage and subsequent degradation of target mRNAs via
the RNAi pathway. The ﬁrst clinical applications of RNAi-
based therapies have been in wet age-related macular
degeneration (wet AMD).
65 To date, only three synthetic
siRNAs have been evaluated by direct intravitreal adminis-
trationfortheirsafetyandefﬁcacyinhumanbeings–onenon-
modiﬁed siRNA (‘Cand5’ or ‘bevasiranib’; Opko Pharmaceu-
ticals, Miami, FL, USA) targeting vascular endothelial growth
factor (VEGF), one partially modiﬁed siRNA (‘Sirna027’ or
‘AGN211745’; Allergan (Irvine, CA, USA)/Sirna Therapeutics
(San Francisco, CA, USA)/Merck (NJ, USA)) targeting its
receptor VEGFR1 and a substantially modiﬁed siRNA
(‘RTP801i’ or ‘PF-04523655’; Quark Pharmaceuticals/Pﬁzer,
Ness Ziona, Israel) targeting RTP801/DDIT4. Clinical trials
with the ﬁrst two siRNAs have been discontinued owing to the
lack of efﬁcacy, whereas the siRNA targeting RTP801 is
currentlyinPhaseIIclinicaltrialsbeingconductedbyPﬁzerfor
the treatment of wet AMD and diabetic macular oedema.
Demonstration of the utility of RNAi in the eye using
synthetic siRNAs has been complicated by the publication
of Kleinman et al.,
66 where it was reported that ‘naked’
Figure 4 Protection of RGC from death by siCASP2 treatment after ONC and ONT. (a) Treatment with siCNL at 7 days post-ONC resulted in 60% RGC death compared
with intact and BDNF-treated controls. Increasing the dose of siCASP2 from 5 to 20mg enhanced RGC survival with 20–35mg per eye, resulting in 100% RGC protection
compared with intact and positive controls. (c) siCASP2 enhanced RGC survival by 15% after ONT compared with the protection afforded by a control siGFP at 14 days after
ONT. (b) and (d) Representative FG back-labelled RGC in retinal whole mounts demonstrate the neuroprotection promoted by siCASP2 treatment after ONC and ONT,
respectively (scale bars (b) and (d)¼100mm). Note: the differences in FG labelling between (b) and (d) are due to the methodology used in the two different laboratories,
please see Materials and Methods for full details
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exert RNAi without facilitating delivery by, for example,
conjugation to cholesterol. Instead, the observed biological
effects (i.e. antiangiogenic effects) were ascribed to triggering
oftoll-likereceptor3thatisasensorfordouble-strandedRNA.
Indeed, nonspeciﬁc effects associated with triggering innate
immune and secondary interferon responses by non-modiﬁed
siRNAshavebeenreportedalsoinothersystems.
67–69Onthe
other hand, non-modiﬁed siRNAs are usually nuclease-labile
and cannot persist in biological ﬂuids for prolonged times,
which too might contribute to their reduced in vivo uptake and
activity. However, chemical modiﬁcations can be used to both
stabilizesyntheticsiRNA against nucleasedegradation andto
abrogate its off-target and immunostimulatory effects. Syn-
thetic siRNAs containing 20-O-methyl, 20-ﬂuoro, 20-deoxy or
locked nucleic acid (LNA) nucleotides have been shown to be
protected from rapid nuclease degradation, thus enhancing
the longevity of the gene silencing function (reviewed in
Robbins et al.
70). Furthermore, selective incorporation of 20-
O-methyl guanosine or 20-O-methyl uridine residues in the
passenger strands of highly immunostimulatory siRNA
molecules completely abrogated siRNA-mediated interferon
responses.
71
The synthetic chemically stabilized siRNA targeting cas-
pase-2 reported here was shown to: (1) be resistant to
nuclease degradation, allowing it to persist in rat retina for up
to 28 days after intravitreal administration; (2) be taken up
effectively by the cells in the rat retina following intravitreal
administration, with the highest accumulation in RGC; (3) not
elicit any interferon or cytokine responses; (4) not exhibit
seed-mediated or passenger-strand mediated off-target
effects; and (5) elicit RNAi-mediated cleavage of caspase-2
mRNA in vivo. These properties support the clinical develop-
ment of siCASP2 described in this communication for ocular
neuroprotection. This siCASP2 is currently being evaluated in
the clinic as a neuroprotective agent for the treatment of
sudden vision loss associated with NAION, and non-invasive
deliverystrategiesarebeingdevelopedforthepotentialuseof
this siRNA to treat glaucoma.
To the best of our knowledge, the studies reported here are
the ﬁrst to explore the potential neuroprotective effects of
intravitreally injected synthetic siRNAs. Only one previous
report has described the use of non-modiﬁed siRNA for the
purpose of ocular neuroprotection.
72 However, the authors
injected siRNAs directly into the ON stump for retrograde
delivery to RGC, an administration route that is not readily
clinically tractable. In contrast, we demonstrate for the ﬁrst
time that synthetic chemically stabilized siRNA can be
delivered to RGC using a clinically relevant delivery route
(intravitreal injection) to exert a strong neuroprotective effect.
The fact that the ‘naked’ (unformulated) siRNA is taken up
efﬁciently after intraocular delivery has an added advantage,
eliminating the need for liposomal and/or viral delivery of the
therapeutic siRNA/short hairpin RNA, thus avoiding potential
safety issues associated with these strategies.
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In conclusion, our results implicate caspase-2 as the
predominant caspase responsible for the death of RGC after
ON injury. Our results also show that stabilized siCASP2
exhibits a long residence time in the rat eye after intravitreal
administration, is taken up readily by RGC, activates RNAi, is
neuroprotective after RGC axotomy and, therefore, may be a
useful therapeutic in ophthalmic diseases that involve RGC
death.
Materials and Methods
Animal care and procedures. Depending on the site of performance,
animal procedures were evaluated and licensed by the UK Home Ofﬁce and
approved by the University of Birmingham Institutional Ethical Review Committee
(AL Laboratory), or were reviewed and approved by Canadian Council on Animal
Care (ADP Laboratory) for the use of experimental animals, or were reviewed and
approved by the Hebrew University Animal Research Committee in Israel (Quark
Laboratories).
siRNA. AllsiRNAmoleculesusedinthisstudyweresimilarlychemicallystabilized
and were synthesized at BioSpring (Frankfurt, Germany). siCASP2 had sequence
50-GCCAGAAUGUGGAACUCCU-30 (sense strand) and was used in all relevant
experiments described in this manuscript. Tracer siRNA having sequence
50-GUGCCAACCUGAUGCAGCU-30 (sense strand) and Cy3 ﬂuorophore at the 30
end of the antisense strand was utilized for ﬂuorescent microscopy. Control siRNA
against GFP had sequence as described previously.
74 Another control siRNA,
siCNL (sense strand: 50-ACUAAAUUACGCGCGAUGC-30), was generated by
random combination of nucleotides and veriﬁed (using Smith–Waterman sequence
comparison algorithm) for the lack of any similarity to human, rat and mouse
transcriptome (RefSeq, NCBI).
siCASP2 stability in vitreous ﬂuid. To monitor siCASP2 degradation by
nucleases in the vitreous, siCASP2 was diluted in Dutch-belted rabbit vitreous
(Bioreclamation, Hicksville, NY, USA) to a ﬁnal concentration of 7mM (86mg/ml)
and incubated at 371C. At time points between 0 and 24h after incubation, 5ml
aliquots were transferred to 15ml of 1.5  TBE-loading buffer, snap frozen in liquid
N2andstoredat 801Cuntiluse.Thealiquotswerethawedoniceandanalysedon
20% non-denaturing polyacrylamide gel in a TBE buffer. Samples were visualized
on an UV-transilluminator subsequent to ethidium bromide staining.
ONC model and counting of RGC. Adult, female 200–250g Wistar rats
(n¼4 eyes per treatment) were anaesthetized intraperitoneally with Hypnorm/
Hypnovel anaesthetic (Janssen Pharmaceuticals, Oxford, UK) and the ON of both
eyes were crushed (ONC) intraorbitally to completely transect all RGC axons
leaving sheath and artery intact. All reagents were intravitreally injected using glass
micropipettesinaﬁnalvolumeof10ml.AnimalsweretreatedwitheitherPBSorwith
20mg control siCNL or with 5, 10 or 20mg siCASP2 or with 5mg BDNF (Peprotech
Ltd, London, UK) immediately after ONC and within 5min post-surgery.
At 5 days post-ONC, 2ml of 4% FG (Cambridge Bioscience, Cambridge, UK)
retrograde tracer was injected into the nerve mid-way between the lamina cribrosa
and the site of ONC. After 48h, animals were killed by exposure to CO2 and
intracardiallyperfusedwith4% formaldehyde (TAAB Laboratories,Aldermaston,UK).
Retinas were dissected out and immersion ﬁxed in 4% formaldehyde (TAAB
Laboratories) for 30min and whole-mounted onto glass slides (VWR International,
Lutterworth, UK). Four equidistal radial cuts were made to give four equally sized
quadrants, attached together around the optic disc. Retinal whole mounts were air
dried and mounted in Vectashield mounting medium (Vector Laboratories,
Peterborough, UK). An observer was blinded to the treatments and groups and
samples were randomly assigned numbers before image capture and analysis.
Images were captured at  20 magniﬁcation using a Zeiss epiﬂuorescent
microscope (Zeiss, Hertfordshire, UK) equipped with a Axiocam HRc camera
(Zeiss) running the Axiovision software (Zeiss). Images were captured from three
different areas of each quadrant (total¼12 counts per quadrant, n¼4 retinas per
treatment, to account for variation of RGC numbers in the different areas and
quantiﬁed using the built-in particle counting facilities in ImagePro; Media
Cybernetics, Bethesda, MD, USA) and expressed as the number of RGC per
mm
2±S.E.M.
ONT model and counting of RGCs. RGCs were labelled by application of
FG in the superior colliculus of adult female Sprague–Dawley rats (180–200g)
(n¼5–6 per group). Both superior colliculi were exposed and a small piece of gel
foamsoakedinFGwasappliedtotheirsurfaceasdescribedpreviously.
75–77After1
week, the entire population of RGCs in the left eye was axotomized by transecting
the ON 0.5–1mm posterior to the globe. With the aid of a standard, upright
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oftheretinalcirculationaftereachaxotomy.Animalsshowingsignsofcompromised
blood supply, identiﬁed by the collapse of vessels in the retinal vasculature and/or
absence of blood ﬂow, were excluded from the study. Intravitreal injections of
10mg/5ml siCASP2 or 10mg/5ml siGFP (both in PBS vehicle) were performed
immediately following the axotomy procedure and then (for the 2nd time) at
7 days post-axotomy into the vitreous body of the left eye. Surgical glue (Indermill,
Tyco Health Care, Mansﬁeld, MA, USA) was used to seal the site of injection.
Experimental and control animals (including those that did not undergo axotomy)
were perfused transcardially with 4% paraformaldehyde 2 weeks after axotomy.
Both eyes were dissected out and post-ﬁxed in 4% paraformaldehyde for an
additional 30min at 41C. Fixed retinas were ﬂat-mounted on Fisherbrand
microscope slides. An observer was blinded to the treatment groups and
samples were randomly assigned numbers before image capture and analysis.
Fluorescence was visualized with a Zeiss Axioskop 2 Plus microscope (Carl Zeiss,
Kirkland, QC, Canada), images were captured with a CCD camera (Retiga
(Qimaging), Surrey, BC, Canada) and processed with the Northern Eclipse image
analysis software (Empix Imaging, Mississauga, ON, Canada). Microphotographs
were taken at  25 magniﬁcation. RGCs were counted in standard retinal areas as
described previously
75–77 and expressed as the number of RGC per mm
2±S.E.M.
InsituhybridizationdetectionofsiRNA. Themethodusedwasbasedon
the procedure described by Nelson et al.
78 with some modiﬁcations. The
hybridization probes were single-stranded oligonucleotides in which every third
position had LNAs. Their primary sequence corresponded to the sense strand of
siCASP2 or siCNL siRNAs. The oligonucleotide probes were end labelled with
[g-
33P]ATP (Easytides ATP; Perkin-Elmer, Waltham, MA, USA) using
polynucleotide kinase (New England Biolabs, Ipswich, MA, USA). In all, 10-mm-
thicksectionsofeyesweredeparafﬁnized,re-hydratedindecreasingconcentrations
of ethanol, de-proteinized with proteinase K, post-ﬁxed in 10% NBF, acetylated in
triethanolamine-acetic anhydride solution, washed in double-distilled water and air-
dried. The eye sections were hybridized overnight at 481C in hybridization buffer
containing 50% formamide, 10% dextran sulphate, 4 SSC, 1  Denhardt’s
solution, 0.25mg/ml salmon sperm DNA, 0.25mg/ml tRNA and 20nM of single-
stranded LNA-modiﬁed siCAPS2 or siCNL hybridization probes. Representative
sections from intact and injected eyes were present on the same slide during the
hybridization process. Following hybridization, the slides were sequentially washed
in 5 SSC, 2 SSC, double-distilled water and air-dried. The hybridized slides
were immersed in photographic emulsion for the periods between 4h and up to 1
week, developed and analysed using a Zeiss Axioskop 2 light microscope (Carl
Zeiss, Thornwood, NY, USA). The images were taken by Spot RT colour camera
(Diagnostic Instruments Inc., Sterling Heights, MI, USA).
Cy3-siRNA detection in isolated RGC. A measure of 40mg of Cy3-
labelled tracer siRNA in 10ml PBS vehicle was injected bilaterally into the vitreous
body of four rats. After 1 or 18h, rats were killed and the injected eyes were
enucleated from two rats per time point and both dissected retinas from the same
animalwere transferredto a tubeﬁlled with PBS containingCa
2þ andMg
2þ. Cells
from each of the two retinal pools were dissociated using ‘Neural Tissue-
Dissociation Kit – Postnatal Neurons’ (Miltenyi Biotec, Auburn, CA, USA; cat. no.
130-094-802) as described in the manufacturer’s protocol. Macrophages were
depleted from the retinal cell suspension by attachment to Anti-Mouse CD11b
Magnetic Particles (BD Biosciences, Franklin Lakes, NJ, USA; cat. no. 558013).
RGCs were next separated using Thy-1 (CD90.1) Microbeads (Miltenyi; cat. no.
130-094-523). Cells were then stained with anti-rat Thy-1 (CD90.1) PerCP-Cy5.5
antibody, and Cy3-siRNA was observed in Thy-1-positive cell population (gated in
Figure 3a) using FACS FL-2 and FL-3 ﬁlters.
Quantitation of siCASP2 in retinas. siCASP2 (35mg per eye) was
delivered by intravitreal injection to the left eyes of adult male Sprague–Dawley rats
(n¼4–6). Rats were euthanized on days 1, 7, 21 or 28 days after the siRNA
injections. Eyes were enucleated and the retinas were carefully separated from the
sclera. Retinas were similarly collected from six untreated rats. Whole retinas were
washed in a large volume of ice-cold PBS and RNA was extracted using EZ-RNA
RNA extractionkit (Biological Industries, Kibbutz Beit-Haemek, Israel). The quantity
of siCASP2 in each of the RNA samples was determined using the Stem & Loop
qPCR method.
79 cDNA was synthesized using 1mg RNA from each sample as
template, a Stem & Loop structured primer (50-GTCGTATCCAGTGCAGGGT
CCGAGGTATTCGCACTGGATACGACGCCAGA-30) and Superscript II Reverse
Transcriptase enzyme (Invitrogen, Carlsbad, CA, USA). qPCR was then carried out
using SYBR Green Master Mix (ABI, New York, NY, USA) and two ampliﬁcation
primers: 50-GGCGGAGGAGTTCCACATTC-30 (forward) and 50-GTGCAGGGTCC
GAGGT-30 (reverse). siRNA quantity was determined by interpolation to a standard
curve generated by qPCR ampliﬁcation of a dilution series of siCASP2 spiked into
normal retina RNA. Measured siRNA quantities were normalized to the geometric
mean of mRNA levels of two reference genes, rat cyclophilin A (Genway, San
Diego, CA, USA) and rat b-actin, which were determined in each sample by qPCR.
Determined siRNA concentration was recalculated per gram retina.
In vivo detection of siCASP2-speciﬁc caspase-2 mRNA cleavage
by RLM-RACE. Adult male 180–220g Sprague–Dawley rats (N¼4 per
treatment group) were subjected to intravitreal injection with 20mg of siCASP2 or
siCNL(non-targetingnegativecontrol)in10mlPBSpereyeorwith10mlPBSalone.
After 4h, retinas were harvested and extracted RNA was subjected to RLM-RACE
analysis for the detection of siCASP2-produced mRNA cleavage product using
Invitrogen GeneRacer Kit, according to the manufacturer’s instructions. The
following primers were used for ampliﬁcation of the caspase-2-RACE-product,
50-TCTGTGGATAGGCGGGACTGCT-30;5 0-GTGAGCAGTAAGTCTTCCAAGTG-
30 (caspase-2-speciﬁc reverse PCR primer); 50-GAGAGGGTTGTGAGCAGTAAG
T-30 (caspase-2-speciﬁc nested reverse PCR primer); 50-CGACTGGAGC
ACGAGGACACTGCAT-30 (adapter-speciﬁc forward PCR primer); and 50-G
GACACTGCATGGACTGAAGGAGTA-30 (adapter-speciﬁc nested forward PCR
primer).RNAsamples extracted fromcultured PC12cells transfectedwith siCASP2
wereused as a positivecontrol. RACEproducts wereseparated on preparativeand
analytical 2% agarose gels. The preparative gel was stained with ethidium bromide
for RACE product visualization. The regions of the gel corresponding to the
predicted size of the RACE ampliﬁcation product were excised and DNA was
extracted using QIAEX II agarose gel extraction kit (Qiagen, Valencia, CA, USA). In
all, 5ng of each DNA extract were used for cloning into pGEM-T Vector (Promega,
Madison, WI, USA). Bacterial colonies harbouring insert-containing plasmids were
isolated and their inserts sequenced to conﬁrm the presence of the expected
adaptor-caspase-2 mRNA junction. The analytical gel was blotted onto a Hybond N
membrane and the blot was hybridized with a RACE product-speciﬁc
oligonucleotide probe (50-GGAGTAGAAATGGAACTCCT-30) labelled with
[g-
33P]ATP (Perkin-Elmer). The hybridization reaction was conducted overnight at
421Cinahybridizationbuffer(6 SSC,1  Denhardt’ssolution(Invitrogen),0.5%
SDS, 0.05% NaPPi (Na4P2O7) (Sigma, St. Louis, MO, USA) and 200mg/ml
sonicatedsalmonspermDNA(Sigma)).Followinghybridization,themembranewas
washed 3  for 15min each at room temperature in 2 SSC, 0.5% SDS solution
andthenexposedovernighttoaKODAKBioMaxﬁlm(Kodak,Rochester,NY,USA).
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